Stratagene Acquisition Gives Agilent Dx Tools, Diversifies Life Sciences Portfolio | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
In a move that will significantly expand its opportunities in the molecular diagnostics field and increase its consumables sales, Agilent said last week that it would acquire Stratagene in a deal valued at roughly $246 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.